Superbugs in Greek Hospitals: What You Need to Know About Antibiotic Resistance
"A new study reveals the latest trends in glycopeptide-resistant enterococci (GRE) and their susceptibility to common antibiotics in a Greek hospital, highlighting the growing threat of antibiotic resistance."
Antibiotic resistance is a growing global health crisis, and the emergence of resistant bacteria in hospitals is a major concern. Among these “superbugs,” glycopeptide-resistant enterococci (GRE) pose a significant threat, limiting treatment options for vulnerable patients. Understanding the trends in antibiotic resistance is crucial for developing effective strategies to combat these infections.
A recent study investigated the antibiotic susceptibility of GRE isolates in a tertiary hospital in Greece. Glycopeptide-resistant enterococci (GRE) were first reported in Europe in 1988 and have since been implicated as causative pathogens in nosocomial infections worldwide. The study focused on how well common antibiotics like linezolid, quinupristin/dalfopristin, tigecycline, and daptomycin worked against these resistant bacteria.
This article breaks down the study’s findings, explaining the implications for patient care, infection control, and the ongoing fight against antibiotic resistance.
Tracking the Resistance Burden
The supplied sources do not provide a specific statistic for antibiotic resistance in Greek hospitals. A study at a tertiary Greek hospital investigated the antibiotic susceptibility of glycopeptide-resistant enterococci (GRE), but the available summary does not report its results. WHO’s 2025 global surveillance report provides adjusted global and regional estimates for 2023 across 93 infection type–pathogen–antibiotic combinations, national estimates for key combinations, and trends for 16 combinations from 2018 to 2023. WHO describes its AMR data portal as a central resource for tracking the global and national response.
Testing and Treatment Challenges
Culture-based methods are among the current approaches for detecting antimicrobial resistance, but a 2024 review says they can be limited by sensitivity, turnaround time, and their ability to detect all potential resistance genes. A 2025 review highlights the threat AMR poses to critically ill patients who rely on antibiotics and discusses challenges and potential solutions in critical care. Another review describes bacterial resistance mechanisms including enzymatic degradation, target modification, efflux pump overexpression, reduced permeability, and biofilm formation. These sources point to diagnostic and treatment challenges, but the summaries do not establish a single accepted approach for Greek hospitals.
Resistance Across Deep Time
Antimicrobial resistance has challenged infectious-disease treatment since the first modern antimicrobials were discovered, according to a historical review. A Harvard Medical School report says a study traced the ancestor of hospital-associated enterococci to about 450 million years ago, around the time animals first crawled onto land. A separate review surveys the antibiotic era and the development and mechanisms of bacterial resistance. These sources describe resistance as a longstanding phenomenon, rather than one that began with a single event.
GRE Resistance: A Snapshot from a Greek Hospital
The study, conducted at the University General Hospital of Heraklion in Crete, Greece, examined 70 consecutive GRE isolates. Of these, 62 were identified as Enterococcus faecium (88.6%), and 8 as Enterococcus faecalis (11.4%). The findings provide a glimpse into the current landscape of antibiotic resistance in this specific hospital setting.
- Linezolid and Daptomycin: All GRE strains remained susceptible to linezolid and daptomycin, offering valuable treatment options.
- Quinupristin/Dalfopristin: Resistance was observed in 17.1% of the isolates. Specifically, all Enterococcus faecalis isolates showed resistance.
- Tigecycline: 11.4% of the isolates were resistant. All Enterococcus faecalis isolates were susceptible to Tigecycline.
Exploring Bacteriocins and Peptides
A review on vancomycin-resistant enterococci notes that these bacteria may also require resistance to other β-lactams and glycopeptide antibiotics such as vancomycin. A separate experimental sepsis study discusses the possibility of using naturally occurring antimicrobial peptides (AMPs), or their derivatives, alone or combined with conventional antibiotics in clinical practice. Its summary presents this as an approach receiving increasing consideration, not as an established treatment. Together, the sources highlight resistance in enterococci and interest in peptide-based strategies.
Susceptibility Does Not Guarantee a Cure
A study summary reports that, among clinical vancomycin-resistant enterococci (VRE) collected in Korea from 1998 to 2005, tigecycline was the most active in vitro among the four antibiotics considered. This is a laboratory susceptibility finding, not evidence in the supplied material that treatment succeeds in patients or that the result applies to Greek hospitals. Harvard Health describes smart antibiotic use as key to controlling the spread of resistant bacteria and superbugs. The sources therefore support a distinction between in-vitro activity and the broader challenge of preventing resistant infections.
Phages as a Potential Alternative
A 2023 review presents supplemental therapies alongside antibiotics as one possible way to address antibiotic-resistant superbugs, though its supplied summary does not report comparative effectiveness. A 2025 World Economic Forum article says phage therapy deployment in animal farming in France is expected to generate more data on its efficacy across different pathogenic bacteria. The article also says reducing antibiotics in the environment and food chain should reduce the spread of resistant bacteria to humans. These sources frame phage therapy as a potential complement or alternative under evaluation, rather than a proven replacement for antibiotics.
Why This Matters: The Bigger Picture of Antibiotic Resistance
The emergence and spread of antibiotic-resistant bacteria like GRE pose a significant threat to public health. These infections are more difficult and costly to treat, leading to longer hospital stays, increased morbidity, and higher mortality rates.
The study emphasizes the critical need for:
<ul><li><b>Judicious Antibiotic Use:</b> Promoting responsible antibiotic prescribing practices to slow down the development of resistance.</li><li><b>Infection Control Measures:</b> Implementing strict hygiene protocols in hospitals and healthcare settings to prevent the spread of resistant organisms.</li><li><b>Continued Surveillance:</b> Monitoring antibiotic susceptibility patterns to detect emerging resistance and guide treatment strategies.</li></ul>